Allergy Therapeuti (NASDAQ:AGYTF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, August 30th.
According to Zacks, “Allergy Therapeutics Plc is a specialty pharmaceutical company focused on allergy vaccination. The company’s product pipeline consists of PollinexTrees(R), Pollinex Grasses + Rye(R), Skin Prick Testing, Diagnostic Products and Service. Allergy Therapeutics Plc is based in Worthing, the United Kingdom. “
Shares of Allergy Therapeuti (AGYTF) opened at 0.39 on Wednesday. Allergy Therapeuti has a 52 week low of $0.39 and a 52 week high of $0.39. The firm’s market capitalization is $231.44 million. The firm has a 50 day moving average price of $0.39 and a 200-day moving average price of $0.39.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allergy Therapeuti Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeuti and related companies with MarketBeat.com's FREE daily email newsletter.